Lipoproteins, HIV, and Antiretroviral Therapy in SMART

SMART 中的脂蛋白、HIV 和抗逆转录病毒治疗

• 批准号: 7355507
• 负责人: DANIEL A DUPREZ
• 金额: $ 37.38万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-01 至 2009-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7355507
• 关键词: Address; Ancillary Study; Anti-Retroviral Agents; Cardiovascular Diseases; Coagulation Process; Data; Data Set; Disease; Disease-Free Survival; Functional disorder; HIV; HIV Infections; Individual; Inflammatory; Lipids; Lipoproteins; Measurement; NMR Spectroscopy; Numbers; Participant; Randomized; Research; Research Infrastructure; Sampling; Specimen; Survival Rate; Upper arm; Viral; abstracting; antiretroviral therapy; base; cardiovascular disorder risk; multidisciplinary; particle; repository; size

DESCRIPTION (provided by applicant): Data from the Strategies for Management of Antiretroviral Therapy (SMART) study indicate that episodic use of antiretroviral treatment (ART) is associated with an increased risk of cardiovascular disease (CVD). The general aim of this ancillary study proposal is to elucidate mechanisms underlying the increased CVD risk in the episodic ART treatment arm of SMART. Three subsamples of the 5,472 trial participants have been identified for measurement of lipid particle number and size by nuclear magnetic resonance (NMR) spectroscopy and for measurement of selected inflammatory and coagulation markers: 1) a random sample of 500 participants randomized to the episodic and viral suppression treatment arms; 2) 250 participants who were ART-na¿ve entry or who had not taken ART for at least 6 months prior to randomization in SMART; and 3) participants who developed CVD (208 cases) and two matched controls (416 participants) for each case. We will take advantage of the trial infrastructure, participant data that will be collected through mid-2007, and the large specimen repository for SMART to efficiently address three aims based on these subsamples. With the extensive and high quality SMART dataset, and the track record of our multidisciplinary team, the findings from this research can be expected to elucidate reasons for increased CVD risk among HIV-infected individuals and advance our understanding of the pathophysiology of CVD in the presence of HIV. Advances in the management of HIV disease and in ART over the last 10 years have let to prolonged disease-free survival in a substantial proportion of individuals with HIV infection. This proposal will produce additional information that will enhance their disease-free survival rate. (End of Abstract)

描述（由申请人提供）： 来自抗逆转录病毒疗法（SMART）研究策略的数据表明，抗逆转录病毒治疗（ART）的发作与心血管疾病（CVD）的风险增加有关。这项辅助研究建议的总体目的是阐明SMART情节艺术治疗部门中CVD风险增加的机制。已经确定了5,472个试验参与者的三个子样本，用于测量脂质颗粒的数量和大小，通过核磁共振（NMR）光谱法以及测量选定的炎症和凝结标记的测量：1）随机样本的500名参与者随机样本随机地随机化为情节和病毒抑制治疗治疗臂； 2）250名参与者，他们的参与者或在Smart随机化之前至少6个月没有服用艺术； 3）每个案例都开发了CVD（208例）和两个匹配的对照（416个参与者）的参与者。我们将利用试验基础架构，将通过2007年中期收集的参与者数据以及SMART的大型标本存储库有效地基于这些子样本来解决三个目标。凭借广泛而高质量的智能数据集以及我们的多学科团队的往绩，这项研究的发现有望阐明受HIV感染者中CVD风险增加的原因，并促进我们在HIV存在下对CVD的病理生理学的理解。在过去的十年中，艾滋病毒疾病和艺术的管理进展已在很大一部分艾滋病毒感染中延长无病生存。提案将产生其他信息，以提高其无病生存率。 （抽象的结尾）